- Home
- MFA vs MLYS Comparison
MFA vs MLYS Comparison
Compare MFA & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFA
- MLYS
- Stock Information
- Founded
- MFA 1997
- MLYS 2019
- Country
- MFA United States
- MLYS United States
- Employees
- MFA N/A
- MLYS N/A
- Industry
- MFA Real Estate Investment Trusts
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- MFA Real Estate
- MLYS Health Care
- Exchange
- MFA Nasdaq
- MLYS Nasdaq
- Market Cap
- MFA 1.1B
- MLYS 893.0M
- IPO Year
- MFA N/A
- MLYS 2023
- Fundamental
- Price
- MFA $10.27
- MLYS $15.93
- Analyst Decision
- MFA Buy
- MLYS Strong Buy
- Analyst Count
- MFA 5
- MLYS 3
- Target Price
- MFA $13.20
- MLYS $27.00
- AVG Volume (30 Days)
- MFA 1.1M
- MLYS 2.1M
- Earning Date
- MFA 05-05-2025
- MLYS 05-08-2025
- Dividend Yield
- MFA 13.97%
- MLYS N/A
- EPS Growth
- MFA 78.26
- MLYS N/A
- EPS
- MFA 0.82
- MLYS N/A
- Revenue
- MFA $279,608,000.00
- MLYS N/A
- Revenue This Year
- MFA N/A
- MLYS N/A
- Revenue Next Year
- MFA $8.97
- MLYS N/A
- P/E Ratio
- MFA $12.57
- MLYS N/A
- Revenue Growth
- MFA 19.47
- MLYS N/A
- 52 Week Low
- MFA $9.36
- MLYS $8.24
- 52 Week High
- MFA $13.45
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- MFA 35.41
- MLYS 59.01
- Support Level
- MFA $10.64
- MLYS $16.15
- Resistance Level
- MFA $10.89
- MLYS $17.21
- Average True Range (ATR)
- MFA 0.21
- MLYS 1.23
- MACD
- MFA -0.06
- MLYS -0.10
- Stochastic Oscillator
- MFA 29.21
- MLYS 46.83
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company is an internally managed real estate investment trust or REIT.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.